Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD)
Looking for a particular Cellestia Biotech employee's phone or email?
Cellestia Biotech Questions
The Cellestia Biotech annual revenue was $6 million in 2026.
Raj Lehal is the CEO of Cellestia Biotech.
8 people are employed at Cellestia Biotech.
Cellestia Biotech is based in Basel, Basel-City.
The NAICS codes for Cellestia Biotech are [541, 5417, 54171, 541711, 54].
The SIC codes for Cellestia Biotech are [2834, 28, 283].
Top Cellestia Biotech Employees
-
Raj Lehal
Chief Executive Officer at Cellestia Biotech
Basel, BS, CH21 -
Charlotte Urech
Senior Research Scientist at Cellestia Biotech
Lausanne, VD, CH -
1
-
Sebastien Lamy
Research Associate at Cellestia Biotech
Lausanne, VD, CH -
Morgane Magnin
Research Associate at Cellestia Biotech
Épalinges, VD, CH1
Related Companies
